Allogene says Phase 1 trial shows 31% response rate for ALLO-316 in CD70-high metastatic kidney cancer

ALLO•2026-07-15

Safety profile

The safety profile was described as manageable, and there were no Grade 5 adverse events in Phase 1b.

Response rates and durability

The recommended Phase 2 regimen delivered a 25% confirmed response rate; 31% in tumors with CD70 TPS ≥50%. Responses lasted 8 to 18+ months; median duration of response was not reached.

Phase 1 TRAVERSE results published

Allogene Therapeutics disclosed Journal of Clinical Oncology publication of Phase 1 TRAVERSE results for ALLO-316 in metastatic renal cell carcinoma.

Allogene says Phase 1 trial shows 31% response rate for ALLO-316 in CD70-high metastatic kidney cancer

Safety profile

Response rates and durability

Phase 1 TRAVERSE results published

Related News

General Mills, ADM, Walmart team to expand regenerative farming across 40,000 Midwest wheat acres

Microsoft, 3M form strategic partnership on AI data center infrastructure

Wall St set to open higher as investors weigh earnings; PayPal jumps

Crescent Energy Co <CRGY.N>: UBS initiates coverage with Buy rating; price target $13

Lucid threatens litigation, demands retraction from eletric-vehicles.com over bankruptcy report